STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment
- 426 Downloads
Uterine cervix cancer is the second most common malignancy in women worldwide with human papillomavirus (HPV) as the etiologic factor. The two main histological variants, squamous cell carcinomas (SCC) and adenocarcinomas (AC), resemble the cell morphology of exocervix and endocervix, respectively. Cancer metabolism is a cancer hallmark conditioned by the microenvironment. As uterine cervix homeostasis is dependent on lactate, we hypothesized lactate plays a role in uterine cervix cancer progression. Using in vitro (SiHa-SCC and HeLa-AC) and BALB-c/SCID models, we demonstrated that lactate metabolism is linked to histological types, with SCC predominantly consuming and AC producing lactate. MCT1 is a key factor, allowing lactate consumption and being regulated in vitro by lactate through the FOXM1:STAT3 pathway. In vivo models showed that SCC (SiHa) expresses MCT1 and is dependent on lactate to grow, whereas AC (HeLa) expresses MCT1 and MCT4, with higher growth capacities. Immunohistochemical analysis of tissue microarrays (TMA) from human cervical tumors showed that MCT1 expression associates with the SCC type and metastatic behavior of AC, whereas MCT4 expression concomitantly increases from in situ SCC to invasive SCC and is significantly associated with the AC type. Consistently, FOXM1 expression is statistically associated with MCT1 positivity in SCC, whereas the expression of FOXO3a, a FOXM1 functional antagonist, is linked to MCT1 negativity in AC. Our study reinforces the role of the microenvironment in the metabolic adaptation of cancer cells, showing that cells that retain metabolic features of their normal counterparts are positively selected by the organ’s microenvironment and will survive. In particular, MCT1 was shown to be a key element in uterine cervix cancer development; however, further studies are needed to validate MCT1 as a suitable therapeutic target in uterine cervix cancer.
KeywordsUterine cervix cancer MCT1 Metabolic symbiosis STAT3-FOXM1 New therapeutic target
The project was funded by Fundação Luso-Americana para o Desenvolvimento (Project FLAD No. 097/2011; PI Jacinta Serpa) and Fundação para a Ciência e a Tecnologia (PTDC\BIM-ONC\1242\2012). The authors would like to thank the Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE (IPOLFG, EPE), for partially supporting the project. The NMR spectrometers are part of the National NMR Facility supported by Fundação para a Ciência e a Tecnologia (RECI/BBB-BQB/0230/2012). Luis G Goncalves acknowledges the grant from the project RECI/BBB-BQB/0230/2012 of Fundação para a Ciência e a Tecnologia.
Compliance with ethical standards
The animal handling and experimental procedures were performed under the rules of the Federation for Laboratory Animal Science Associations (FELASA), accomplishing the 3Rs through evidence-based guidelines.
- 1.González MA. Molecular biology of cervical cancer. Clin Transl Oncol. 2007;9:347–54.Google Scholar
- 5.Gupta S. A comprehensive textbook of obstetrics and gynecology. First. India: Jaypee Brothers Medical Publishers Ltd; 2011. p. 628.Google Scholar
- 9.Yarbrough VL, Winkle S, Herbst-Kralovetz MM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Human reproduction update [Internet]. 2014 [cited 2015 Feb 23];0:1–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25547201.
- 10.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. Elsevier Inc.; 2011;144:646–74.Google Scholar
- 13.Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and oncology. Elsevier Ireland Ltd; 2009;92:329–33.Google Scholar
- 20.Tian Q, Li Y, Wang F, Li Y, Xu J, Shen Y, et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst [Internet]. 2014 [cited 2015 Feb 23];106. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4188123&tool=pmcentrez&rendertype=abstract.
- 22.Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SMM, Etlinger D, Moreira MAR, et al. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol. 2008;27:568–74.Google Scholar
- 26.Zhou Y, Li M, Wei Y, Feng D, Peng C, Weng H, et al. Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res. 2009;29:695–703.Google Scholar
- 27.Mencalha AL, Binato R, Ferreira GM, Du Rocher B, Abdelhay E. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One. 2012;7.Google Scholar
- 29.Chen J, Lee H-J, Wu X, Huo L, Kim S-J, Xu L, et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer research [Internet]. 2015 [cited 2015 Jan 2];75:554–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25511375.
- 33.O’Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis. BioMed Central Ltd; 2011;11:200.Google Scholar
- 36.Zhao F, Lam EW-F. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Frontiers of medicine [Internet]. 2012 [cited 2015 Aug 27];6:376–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23124885.
- 37.McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular cancer therapeutics [Internet]. 2009 [cited 2015 Sep 10];8:582–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19276163.